← Back to Search

Monoclonal Antibodies

Ilumya for Psoriasis

Phase 4
Recruiting
Research Sponsored by Psoriasis Treatment Center of Central New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 16 weeks
Awards & highlights

Study Summary

This trial will test the effectiveness of Ilumya, a new psoriasis treatment, either alone or in combination with Halog ointment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~16 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 16 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Body surface area

Trial Design

1Treatment groups
Experimental Treatment
Group I: IlumyaExperimental Treatment1 Intervention
Ilumya 100mg subcutaneous at weeks 0, 4 and 16.

Find a Location

Who is running the clinical trial?

Psoriasis Treatment Center of Central New JerseyLead Sponsor
14 Previous Clinical Trials
417 Total Patients Enrolled
13 Trials studying Psoriasis
377 Patients Enrolled for Psoriasis
Sun Pharmaceutical Industries LimitedIndustry Sponsor
64 Previous Clinical Trials
13,486 Total Patients Enrolled
13 Trials studying Psoriasis
2,710 Patients Enrolled for Psoriasis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~5 spots leftby Apr 2025